Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04461171 · ClinicalTrials.gov registry record · NA

Enhanced Recovery After Surgery in Extremity Sarcoma

A NA study of Sarcoma, sponsored by Joshua Lawrenz.

Recruiting
Registry status
NA
Development phase
120
Enrollment target
1
Study location

NCT04461171 is a NA study of Sarcoma that is actively recruiting participants, run by Joshua Lawrenz. The registered enrollment target is 120 participants, below the 920-participant average among 122 other Sarcoma trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04461171, a NA study of Sarcoma, is actively recruiting participants, sponsored by Joshua Lawrenz.

RECRUITING
Registry status
NA
Development phase
120 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to demonstrate the efficacy of implementing the enhanced recovery after surgery (ERAS) pathway in a prospective manner to patients undergoing surgical treatment for extremity sarcoma.

Conditions Studied

Interventions

  • PROCEDURE Enhanced Recovery After Surgery

Study Locations (1)

Tennessee

  • Vanderbilt University Medical Center - Nashville

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2020-12-14
Est. Completion 2026-06
Phase NA

Sponsor

Joshua Lawrenz

1 total trials

What the Registry Record Tells You About NCT04461171

The ClinicalTrials.gov registry entry for NCT04461171 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 920-participant average among 122 other Sarcoma trials with a reported enrollment target (87% lower). The listed sponsor is Joshua Lawrenz, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Sarcoma appearing as the primary indexed condition, and to 1 intervention - of which Enhanced Recovery After Surgery is the first listed.

NCT04461171 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.

Frequently Asked Questions

What is clinical trial NCT04461171 about?

NCT04461171 is a clinical study titled "Enhanced Recovery After Surgery in Extremity Sarcoma". The purpose of this study is to demonstrate the efficacy of implementing the enhanced recovery after surgery (ERAS) pathway in a prospective manner to patients undergoing surgical treatment for extremity sarcoma.

What is the current status of trial NCT04461171?

This trial is currently recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2020-12-14. Estimated completion is 2026-06.

What conditions does trial NCT04461171 study?

This clinical trial studies the following conditions: Sarcoma.

What interventions are being tested in trial NCT04461171?

The interventions under investigation include: Enhanced Recovery After Surgery (PROCEDURE).

Who is sponsoring clinical trial NCT04461171?

This trial is sponsored by Joshua Lawrenz, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04461171 being conducted?

This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Sarcoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.